Hector M Garcia-Garcia, Ron Waksman, Gebremedhin D Melaku, Mohil Garg, Solomon Beyene, Adrian Wlodarczak, Ajay Kerai, Molly B Levine, René J van der Schaaf, Jan Torzewski, Bert Ferdinande, Javier Escaned, Juan F Iglesias, Johan Bennett, Gabor G Toth, Michael Joner, Ralph Toelg, Marcus Wiemer, Göran Olivecrona, Paul Vermeersch, Michael Haude
AIMS: To assess the impact of the baseline plaque composition on the DREAMS 3G luminal late loss and to compare the serial plaque changes between baseline and 6-month (6 M), and 12-month (12 M) follow-up. METHODS AND RESULTS: A total of 116 patients were enrolled in the BIOMAG-I trial. Patients were imaged with optical coherence tomography (OCT) pre- and post-DREAMS 3G implantation and at 6 and 12 months. OCTPlus software uses artificial intelligence to assess composition (i...
November 4, 2023: European Heart Journal Cardiovascular Imaging